US2010047215A1PendingUtilityA1

Stem cell targeting methods

65
Individually held — no corporate assignee on recordPriority: Mar 15, 2002Filed: Oct 30, 2009Published: Feb 25, 2010
Est. expiryMar 15, 2022(expired)· nominal 20-yr term from priority
Inventors:Catherine PhillipsJulian P. Breillatt, Jr.
A61P 35/00A61P 9/00A61P 37/00A61P 37/02A61K 38/1741A61P 11/00A61K 35/34A61K 35/28A61K 35/51A61K 47/50A61K 47/64C12N 15/85A61K 35/12A61K 35/50A61K 47/549A61K 35/17
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to methods for delivering stem cells to a target tissue in a mammal using glycoconjugate to traffic the stem cells to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the bone marrow or from umbilical cord tissue. The methods are also useful for targeting a gene of interest to a tissue in a mammal by introducing a cell containing the gene of interest and administering a glycoconjugate to the mammal.

Claims

exact text as granted — not AI-modified
1 . A method for directing stem cells to a target tissue on a subject, comprising administering to the subject (i) a composition comprising an asialoglycoprotein receptor blocker, and (ii)(a) when the target tissue is heart tissue, a composition comprising hematopoietic stem cells, or (ii)(b) when the target tissue is liver tissue, a composition comprising mesenchymal stem cells. 
   
   
       2 . A method according to  claim 1  wherein the stem cells are CD34 +  stem cells. 
   
   
       3 . A method according to  claim 1  wherein when the target tissue is heart tissue, the hematopoietic stem cells are CD34 +  hematopoietic stem cells, and when the target tissue is liver tissue, the mesenchymal stem cells are selected from the group consisting of stromal cells from bone marrow, stromals cell from liposuction fat, and stromal progenitor cells from a cord blood-depleted expelled placenta. 
   
   
       4 . A method according to  claim 1  wherein the asialoglycoprotein receptor blocker is asialoorosomucoid. 
   
   
       5 . A method according to  claim 1  wherein the asialoglycoprotein receptor blocker is selected from the group consisting of asialofetuin, galactose-bonded polylysine, galactose-bonded polyglucoseamine, and a glycoprotein comprising a carbohydrate structure selected from the group consisting of carbohydrate structures A, B, C, and D in  FIG. 3 . 
   
   
       6 . A method according to  claim 5  wherein the glycoprotein is a human serum glycoprotein. 
   
   
       7 . A method according to  claim 1  wherein the composition comprising the asialoglycoprotein receptor blocker is administered before the composition comprising the stem cells is administered. 
   
   
       8 . A method according to  claim 1  wherein the composition comprising the asialoglycoprotein receptor blocker is administered before and after the composition comprising the stem cells is administered. 
   
   
       9 . A method according to  claim 1  wherein the composition comprising the asialoglycoprotein receptor blocker is administered during administration of the composition comprising the stem cells. 
   
   
       10 . A method according to  claim 1  wherein the subject is a human subject. 
   
   
       11 . A method according to  claim 1  wherein the stem cells comprise a therapeutic gene. 
   
   
       12 . A method for directing asialodeterminant-bearing stem cells to a target tissue in a subject, comprising administering to the subject (i) a composition comprising an asialoglycoprotein receptor blocker, and (ii)(a) when the target tissue is heart tissue, a composition comprising asialodeterminant-bearing stem cells, wherein the asialodeterminant-bearing stem cells are not mesenchymal stem cells but are optionally hematopoietic stem cells or (ii)(b) when the target tissue is liver tissue, a composition comprising asialodeterminant-bearing stem cells, wherein the asialodeterminant-bearing stem cells are not hematopoietic stem cells but are optionally mesenchymal stem cells. 
   
   
       13 . A method according to  claim 11  wherein the asialoglycoprotein receptor blocker is asialoorosomucoid. 
   
   
       14 . A method according to  claim 11  wherein the asialoglycoprotein receptor blocker is selected from the group consisting of asialofetuin, a galactose-bonded polylysine, a galactose-bonded polyglucoseamine, and a glycoprotein comprising a carbohydrate structure selected from the group consisting of carbohydrate structures A, B, C, and D in  FIG. 3 . 
   
   
       15 . A method according to  claim 13  wherein the glycoprotein is a human serum glycoprotein. 
   
   
       16 . A method according to  claim 11  wherein the composition comprising the asialoglycoprotein receptor blocker is administered before the composition comprising the stem cells is administered. 
   
   
       17 . A method according to  claim 11  wherein the composition comprising the asialoglycoprotein receptor blocker is administered before and after the composition comprising the stem cells is administered. 
   
   
       18 . A method according to  claim 11  wherein the composition comprising the asialoglycoprotein receptor blocker is administered during administration of the composition comprising the stem cells. 
   
   
       19 . A method according to  claim 11  wherein the subject is a human subject. 
   
   
       20 . A method according to  claim 11  wherein the stem cells comprise a therapeutic gene.

Join the waitlist — get patent alerts

Track US2010047215A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.